RL
Rokote Laboratories is developing a nasal spray vaccine for SARS-CoV-2, leveraging research from Finnish universities to enhance immune response through mucosal administration. The company addresses the need for effective vaccination against emerging coronavirus variants, aiming to improve vaccine accessibility and self-sufficiency in Finland and Europe.
Helsinki, FinlandFounded 2020
Updated 4 months ago
Funding
$10.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Rokote Laboratories is developing a nasal spray vaccine for SARS-CoV-2, leveraging research from Finnish universities to enhance immune response through mucosal administration. The company addresses the need for effective vaccination against emerging coronavirus variants, aiming to improve vaccine accessibility and self-sufficiency in Finland and Europe.